Abstract

Case Report

Epstein-Barr infection causing toxic epidermal necrolysis, hemophagocytic lymphohistiocytosis and cerebritis in a pediatric patient

Aikaterini Solomou*, Vasileios Patriarcheas, Pantelis Kraniotis and Andreas Eliades

Published: 18 March, 2020 | Volume 4 - Issue 1 | Pages: 015-019

Toxic epidermal necrolysis -the most serious variant of Steven Johnson Syndrome -arises as the result of cell-mediated cytotoxic reaction against keratinocytes. Most common inciting factors include drugs, and infections. On the other hand, Hemophagocytic lymphohistiocytosis (HLH), is a syndrome characterized by enormous immune response in the absence of down-regulation of activated immune cells resulting in cytokine storm causing severe tissue damage.

Up to date, several cases of concomitance of Toxic Epidermal Necrolysis (TEN) and Hemophagocytic Lympohystiocytosis (HLH) in pediatric patients have been reported. Both situations can be fatal and pediatricians should be aware that these two clinical entities are not mutually exclusive, to the contrary they may coexist.

We herein describe a case of Toxic Epidermal Necrolysis, complicated with Hemophagocytic Lymphohistiocytosis with Central Nervous System involvement due to EBV infection.

Read Full Article HTML DOI: 10.29328/journal.acr.1001032 Cite this Article Read Full Article PDF

References

  1. Stern RS, Divito SJ. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Associations, Outcomes, and Pathobiology-Thirty Years of Progress but Still Much to Be Done. J Invest Dermatol. 2017; 137: 1004–1008. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28411832
  2. Nassif A1, Bensussan A, Boumsell L, Deniaud A, Moslehi H, et al. Toxic epidermal necrolysis: Effector cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol. 2004; 114: 1209-1215. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15536433
  3. Ferrandiz-Pulido C1, Garcia-Patos V. A review of causes of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. Arch Dis Child. 2013; 98: 998-1003. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23873883
  4. Levi N1, Bastuji-Garin S, Mockenhaupt M, Roujeau JC, Flahault A, et al. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis. Pediatrics. 2009; 123: 297–304. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/19153164
  5. Kunimi Y, Hirata Y, Aihara M, Yamane Y, Ikezawa Z. Statistical analysis of Stevens-Johnson syndrome caused by Mycoplasma pneumonia infection in Japan. Allergol Int. 2011; 60: 525–532. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22113160
  6. Macedo FI1, Faris J, Lum LG, Gabali A, Uberti JP, et al. Extensive toxic epidermal necrolysis versus acute graft versus host disease after allogenic hematopoietic stem-cell transplantation: challenges in diagnosis and management. J Burn Care Res. 2014; 35: e431-5. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/24476990
  7. Harris V, Jackson C, Cooper A. Review of Toxic Epidermal Necrolysis. Int J Mol Sci. 2016; 17: 2135. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5187935/
  8. Revuz J, Roujeau JC, Guillaume JC, Penso D, Touraine R. Treatment of toxic epidermal necrolysis. Créteil's experience. Arch Dermatol. 1987; 123: 1156. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/3631999
  9. Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention and treatment. J Am Acad Dermatol. 2013; 69: 187.e1. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23866879
  10. Larroche C. Hemophagocytic lymphohistiocytosis in adults: diagnosis and treatment. Joint Bone Spine. 2012; 79: 356-361. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22464018
  11. George MR. Hemophagocytic lymphohistiocytosis: review of etiologies and management. J Blood Med. 2014; 5: 69–86. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4062561/
  12. Aricò M1, Janka G, Fischer A, Henter JI, Blanche S, et al. Hemophagocytic lymphohis- tiocytosis: Diagnosis, treatment and prognostic factors. Report of 122 children from the international registry. Leukemia 1996; 10: 197-203. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/8637226
  13. Henter JI1, Horne A, Aricó M, Egeler RM, Filipovich AH, et al. HLH‐2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr. Blood Cancer. 48: 124-131. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16937360
  14. Fardet L1, Galicier L, Vignon-Pennamen MD, Regnier S, Noguera ME, et al. Frequency, clinical features and prognosis of cutaneous manifestations in adult patients with reactive haemophagocytic syndrome. Br J Dermatol. 2010; 162: 547–553. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/19818067
  15. Sniderman JD, Cuvelier GD, Veroukis S, Hansen G. Toxic epidermal necrolysis and hemophagocytic lymphohistiocytosis: a case report and literature review. Clin Case Rep. 2015; 3: 121–125. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4352368/
  16. Fan ZD, Qian XQ, Yu HG. Pancytopenia as an early indicator for Stevens-Johnson syndrome complicated with hemophagocytic lymphohistiocytosis: a case report. BMC Pediatr. 2014; 14: 38. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/24512039
  17. Kawachi Y, Itoh M, Fujisawa Y, Furuta J, Nakamura Y, et al. Epidermal cell necrosis with direct epidermal infiltration of Epstein-Barr virus (EBV)-encoded small nuclear RNA-positive T lymphocytes in a patient with EBV-associated haemophagocytic syndrome. Br J Dermatol. 2007; 157: 1053-1056. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17725675
  18. Zeng H. Chen X. First case report of Stevens-Johnson syndrome complicated with macrophage activation syndrome. Rheumatol Rep. 2009; 1: 30–31.
  19. Sharma N, Clark J, Pham H, Efron D, MacGregor D, et al. TEN-like eruption in setting of EBV positive T-cell lymphoproliferative disease with HLH, in a child. Australas. J Dermatol. 2013; 55: e44–e47. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23573996
  20. Pakran J, Pavithran K, Kuruvila S, Anand M. Coexistence of Stevens-Johnson syndrome and hemophagocytic syndrome. Indian J Pediatr Dermatol. 2013; 14: 83.
  21. Horne A, Wickström R, Jordan MB, Yeh EA, Naqvi A, et al. How to Treat Involvement of the Central Nervous System in Hemophagocytic Lymphohistiocytosis? Curr Treat Options Neurol. 2017; 19: 3. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5290057/
  22. Henter J-I, Nennesmo I. Neuropathologic findings and neurologic symptoms in twenty-three children with hemophagocytic lymphohistiocytosis. J Pediatrics. 1997; 130: 358–365. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5290057/
  23. Shieh AC, Guler E, Smith DA, Tirumani SH, Beck RC, et al. Hemophagocytic Lymphohistiocytosis: A primer for Radiologists. AJR Am J Roentgenol. 2020; 214: W11-W19. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/31532253

Figures:

Figure 1

Figure 1

Figure 1

Figure 2

Figure 1

Figure 3

Figure 1

Figure 4

Figure 1

Figure 5

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More